Albemarle Corporation
ALB - NYSE - $203.52 ▲ +%2.61
-
Earnings Wed 29 Jul

Albemarle opens the
books on Wednesday evening.

12 analysts' median target is $189[FMP target], stock is $204, -7.1% upside potential. After Q1 +137.9% EPS beat[FMP earnings], the stock moved +3.0%.

↓ summary below
Quick Take - in 40 seconds
C-
SELL Council 1/6 - Moonshot 50

C- = MoonshotScore 50[9-pillar formula] + Council 1/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $1.5B[FMP est], EPS $2.21[FMP est]. 1 consecutive quarters of beat[FMP earnings].

Detailed analysis below ↓
$2.21 EPS Estimate Last year $-0.53 - +1909% YoY YoY
1 Beat Streak Expectations beaten consecutively for the last 1 quarters

Q1 EPS +137.9% beat[FMP] but the stock +3.0% D+1[FMP D+1]. Neal Sheorey promised $98.7M CapEx + a sequential decline in Q4 during the Q1 earnings call[Neal Sheorey capex transcript].

Watchlist

5 metrics stand out this quarter.

$1.3 billion Expectation / Guide

Specialties Guidance Increase

specialties_guidance_increase

We are raising our 2026 outlook for Specialties net sales between $1.3 billion and $1.5 billion and adjusted EBITDA outlook between $225 million and $275 million, reflecting higher pricing and volumes in our Specialties business.

"As Neal will share shortly, we are raising our 2026 outlook for Specialties net sales between $1.3 billion and $1.5 billion and adjusted EBITDA outlook between $225 million and $275 million, reflecting higher pricing and volumes in our Specialties business."

- Jerry Masters, CEO - Q1 FY26 Earnings Call - May 7, 2026
37% Investor Focus

Lithium Demand Growth

lithium_demand_growth

So far this year, lithium consumption is up 37%, towards the upper range of our 2026 forecast of 15% to 40%.

"So far this year, lithium consumption is up 37%, towards the upper range of our 2026 forecast of 15% to 40%."

- Jerry Masters, CEO - Q1 FY26 Earnings Call - May 7, 2026
$40 million Investor Focus

Cost Productivity Improvements

cost_productivity_improvements

Year-to-date, we've delivered $40 million in cost and productivity improvements and remain on track to hit our full year target of $100 million to $150 million.

"Moreover, year-to-date, we've delivered $40 million in cost and productivity improvements and remain on track to hit our full year target of $100 million to $150 million."

- Jerry Masters, CEO - Q1 FY26 Earnings Call - May 7, 2026
%117 Investor Focus

Energy Storage Growth

energy_storage_growth

Energy storage demand showed strong growth, up 117% year-over-year.

"We are maintaining our outlook for strong lithium market growth led by energy storage demand, which is up 117% year-over-year."

- Jerry Masters, CEO - Q1 FY26 Earnings Call - May 7, 2026
$1.3 billion Investor Focus

Debt Reduction

debt_reduction

In the first quarter, the company repaid $1.3 billion of debt, further strengthening its balance sheet and reducing interest expense.

"In the first quarter, following the successful sales of our Eurecat joint venture and the controlling stake in Ketjen, we repaid $1.3 billion of debt, further strengthening our balance sheet and reducing interest expense."

- Jerry Masters, CEO - Q1 FY26 Earnings Call - May 7, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

MoonshotScore 50 / 100

9-pillar methodology. Cash Runway and Price Momentum strong. Operating Leverage weak.

How is it calculated? ->
Revenue Growth4.0Q1 vs Q2: moderate growth (+7.4%)
Gross Margin4.0Q1: average margin (35.1%)
Operating Leverage2.0op margin healthy (16.3%)
Cash Runway10.0FCF very strong ($0.2B, 2.5x CapEx)
R&D Intensity3.0low R&D investment (0.8%, weak innovation)
Price Momentum7.0RSI 59.3 positive momentum, 50d above
News Sentiment5.0mixed (46% buy)
Council Score 1 / 6 Bullish

6 investor frameworks. 1 bullish (Ken Griffin), 2 bearish (Klarman, Munger), 3 neutral (Ray Dalio, Jim Simons, Buffett).

How is it calculated? ->
Ray Dalio macro - target upside -7.1%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 59
Klarman value - target upside -7.1%
Buffett quality - ROE score 1/5
Munger valuation - target upside -7.1%
Munger's Mindset character & balance sheet lens
Overvalued

Quality business, but price is high.

How is it calculated? ->
Financial HealthWeak
Margin of SafetyWeak
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
59.3 RSI 59.3 positive momentum, 50d above
MACD
+12.90 price above 50d - support positive
50d MA
$180 stock 12.9% above - short-term support
200d MA
$133 stock 53.1% above - long-term support
Volume (10d)
+47% increase - pre-earnings positioning
Resistance
$189
Analyst median target - upgrade trigger if broken
Current
$204
Pre-earnings position
Support
$113
Invalidation - close below this is a technical breakdown
Pattern
Range
$113-$189 band - earnings breakout/breakdown trigger

Past Performance

Albemarle's last 8 quarters: 1 consecutive beats.

BEAT
Q2 FY25
$0.11 vs $-0.83 est - -1.5%
BEAT
Q3 FY25
$-0.19 vs $-0.86 est - -0.8%
MISS
Q4 FY25
$-0.53 vs $-0.42 est - -9.4%
BEAT
Q1 FY26
$2.95 vs $1.24 est - +3.0%

Q1 (May 7, 2026): EPS $2.95 vs $1.24 est[FMP], +137.9% beat. D+1 movement: +3.0%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $2.14 (no guidance)

Q1: EPS $2.95 vs $1.24 beat[FMP], stock +3.0% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $98.7M[FMP cashflow]. Q1 op margin 16.3%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $2.21 + CapEx discipline
Threshold: EPS > $2.21[FMP est].
Target: Break above median target $189[FMP target]; high target $264[FMP] upper bound.
Scenario B - In-Line
EPS approx $2.21 + CapEx < $98.7M
Threshold: EPS approx $2.21[FMP est], Q4 CapEx < $98.7M[FMP].
Target: Consolidation in the band between current $204[FMP] and median $189[FMP].
Scenario C - Miss
EPS < $2.14 or CapEx >= $98.7M
Threshold: EPS < $2.14[FMP estx0.97].
Target: Current $204 below SMA200 $133[FMP], if rejection continues, $113[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 12 analysts say?

Wall Street Consensus
$189
12-month median target price (-7.1% upside potential)
11
BUY
13
HOLD
0
SELL
Risk Management
$113
Invalidation level - critical support threshold
$180 - 50-day MA (above, +12.9%)
$133 - 200-day MA (above, +53.1%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - ALB Q4 FY26
C-

You read it in 5 minutes. When the numbers come out on Wednesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Wednesday evening. The framework is ready on this page: Q4 EPS threshold $2.21[FMP], CapEx threshold "below $98.7M"[Neal Sheorey]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Try Pro free for 14 days ALB dossier ->

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 29, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 30, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 12, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 29, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the ALB earnings preview cover?

This ALB (ALB) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in ALB earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.